Topics:

Kidney Cancer

Study Validates Prognostic Value of mTOR Pathway Markers in RCC

An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.

Kidney Cancer

Marked differences in renal cell carcinoma subtype were observed by race and sex in patients who underwent nephrectomy at a large tertiary care academic center.

An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.

In patients with non–clear cell RCC, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

A 71-year-old woman presented with back pain and was incidentally found to have a left upper pole renal mass. She underwent left open partial nephrectomy; the pathology results revealed a 2.2-cm clear-cell renal cell carcinoma (RCC) with negative margins and a Fuhrman nuclear grade of 2.

Patient exposure to metformin before undergoing nephrectomy for renal cell carcinoma may have an effect on patient survival, according to a new study.

Preoperative levels of C-reactive protein may be as predictive of outcomes as pathological TNM stage or tumor grade for prognosis in renal cell carcinoma.

Pages

Subscribe to Kidney Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.